We also characterized the overall CD4+ T cells in PBMCs harvested from TC-1 tumor-bearing mice on day 32 after the TC-1 tumor cell challenge in groups treated with pBI-11 DNA delivered through different routes of administration versus untreated. This evidence concerns the gene CD4 and neoplasm.